New drug tested for stubborn kidney condition
NCT ID NCT04983888
Summary
This study tested whether the drug Obinutuzumab could help adults with a specific, difficult-to-treat kidney disease called primary FSGS. It involved 20 participants whose disease had not improved with standard treatments like steroids or other immunosuppressants. Researchers measured if the drug safely reduced protein in the urine, a key sign of kidney damage, over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.